The DOI matches its Crossref record; 210 of the 210 references it cites were found in a registry or an index.
Therapeutics of Neurotransmitters in Alzheimer’s Disease
Open accessAbstract
Alzheimer’s disease (AD) is a progressive neurodegenerative disease, characterized by the loss of memory, multiple cognitive impairments and changes in the personality and behavior. Several decades of intense research have revealed that multiple cellular changes are involved in disease process, including synaptic damage, mitochondrial abnormalities and inflammatory responses, in addition to formation and accumulation of amyloid-β (Aβ) and phosphorylated tau. Although tremendous progress has been made in understanding the impact of neurotransmitters in the progression and pathogenesis of AD, we still do not have a drug molecule associated with neurotransmitter(s) that can delay disease process in elderly individuals and/or restore cognitive functions in AD patients. The purpose of our article is to assess the latest developments in neurotransmitters research using cell and mouse models of AD. We also updated the current status of clinical trials using neurotransmitters’ agonists/antagonists in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Glutamate receptor ion channels
Mayer, M. L. (2005) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2005.05.004 · Cited by 3,640
The Glutamate Receptor Ion Channels
Dingledine, R., Borges, K., Bowie, D., & Traynelis, S. F. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01394-2 · Cited by 3,554
Acetylcholine as a Neuromodulator: Cholinergic Signaling Shapes Nervous System Function and Behavior
Picciotto, M. R., Higley, M. J., & Mineur, Y. S. (2012) · Neuron · doi:10.1016/j.neuron.2012.08.036 · Cited by 1,404
Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I., & for the Memantine Study Group (2004) · JAMA · doi:10.1001/jama.291.3.317 · Cited by 1,403
McShane, R., Areosa Sastre, A., & Minakaran, N. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub5 · Cited by 1,155
(1987) · Comparative Biochemistry and Physiology Part A: Physiology · doi:10.1016/0300-9629(87)90455-5 · Cited by 1,122
Role of Glutamate and NMDA Receptors in Alzheimer’s Disease
Wang, R., & Reddy, P. H. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160763 · Cited by 1,009
Self-citationNovelli, A., Reilly, J. A., Lysko, P. G., & Henneberry, R. C. (1988) · Brain Research · doi:10.1016/0006-8993(88)90765-2 · Cited by 971
Parsons, C. G., Danysz, W., & Quack, G. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00019-2 · Cited by 878
Hepatotoxic Effects of Tacrine Administration in Patients With Alzheimer's Disease
Watkins, P. B. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510370044030 · Cited by 829
GABA from reactive astrocytes impairs memory in mouse models of Alzheimer's disease
Jo, S., Yarishkin, O., Hwang, Y. J., Chun, Y. E., Park, M., Woo, D. H., Bae, J. Y., Kim, T., Lee, J., Chun, H., et al. (2014) · Nature Medicine · doi:10.1038/nm.3639 · Cited by 783
Donepezil and memantine for moderate-to-severe Alzheimer's disease
Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106668 · Cited by 782
Therapeutics of Alzheimer's disease: Past, present and future
Anand, R., Gill, K. D., & Mahdi, A. A. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.07.004 · Cited by 747
Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology
Moreira, P. I., Carvalho, C., Zhu, X., Smith, M. A., & Perry, G. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.10.006 · Cited by 734
Parsons, C. G., Stöffler, A., & Danysz, W. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.07.013 · Cited by 707
Common neurodegenerative pathways in obesity, diabetes, and Alzheimer's disease
Pugazhenthi, S., Qin, L., & Reddy, P. H. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.04.017 · Cited by 697
Self-citationFredholm, B. B., Chen, J.-F., Cunha, R. A., Svenningsson, P., & Vaugeois, J.-M. (2005) · International Review of Neurobiology · doi:10.1016/s0074-7742(05)63007-3 · Cited by 692
Chen, H., Pellegrini, J., Aggarwal, S., Lei, S., Warach, S., Jensen, F., & Lipton, S. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-11-04427.1992 · Cited by 629
Neuroprotection by adenosine in the brain: From A1 receptor activation to A2A receptor blockade
Cunha, R. A. (2005) · Purinergic Signalling · doi:10.1007/s11302-005-0649-1 · Cited by 537
The significance of the cholinergic system in the brain during aging and in Alzheimer’s disease
Schliebs, R., & Arendt, T. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0579-2 · Cited by 530
Mechanism of action of memantine
JOHNSON, J., & KOTERMANSKI, S. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.09.007 · Cited by 502
Oxidative stress in Alzheimer disease: A possibility for prevention
Bonda, D. J., Wang, X., Perry, G., Nunomura, A., Tabaton, M., Zhu, X., & Smith, M. A. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.04.005 · Cited by 483
Arendash, G. W., Schleif, W., Rezai-Zadeh, K., Jackson, E. K., Zacharia, L. C., Cracchiolo, J. R., Shippy, D., & Tan, J. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.07.021 · Cited by 457
Acetylcholinesterase-rich projections from the basal forebrain of the rhesus monkey to neocortex
Mesulam, M.-M., & Van Hoesen, G. W. (1976) · Brain Research · doi:10.1016/0006-8993(76)90385-1 · Cited by 426
Danysz, W., & Parsons, C. G. (2003) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.938 · Cited by 404
Mechanisms of excitotoxicity in neurologic diseases
Beal, M. F. (1992) · The FASEB Journal · doi:10.1096/fasebj.6.15.1464368 · Cited by 388
Chalmers, D. T., & Watson, S. J. (1991) · Brain Research · doi:10.1016/0006-8993(91)90748-k · Cited by 387
Nyth, A. L., & Gottfries, C. G. (1990) · British Journal of Psychiatry · doi:10.1192/bjp.157.6.894 · Cited by 379
Dall'Igna, O. P., Fett, P., Gomes, M. W., Souza, D. O., Cunha, R. A., & Lara, D. R. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2006.08.008 · Cited by 372
Does caffeine intake protect from Alzheimer's disease?
Maia, L., & De Mendonça, A. (2002) · European Journal of Neurology · doi:10.1046/j.1468-1331.2002.00421.x · Cited by 357
Canas, P. M., Porciúncula, L. O., Cunha, G. M. A., Silva, C. G., Machado, N. J., Oliveira, J. M. A., Oliveira, C. R., & Cunha, R. A. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3728-09.2009 · Cited by 357
Nucleus raphe dorsalis in Alzheimer's disease: Neurofibrillary tangles and loss of large neurons
Yamamoto, T., & Hirano, A. (1985) · Annals of Neurology · doi:10.1002/ana.410170608 · Cited by 338
Coyle, J., & Kershaw, P. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01101-x · Cited by 335
Parsons, C. G., Danysz, W., Dekundy, A., & Pulte, I. (2013) · Neurotoxicity Research · doi:10.1007/s12640-013-9398-z · Cited by 331
The histamine H3 receptor: from discovery to clinical trials with pitolisant
Schwartz, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01286.x · Cited by 318
Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines
Rogawski, M. A. (1993) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(93)90005-5 · Cited by 313
Parsons, C. G., Quack, G., Bresink, I., Baran, L., Przegalinski, E., Kostowski, W., Krzascik, P., Hartmann, S., & Danysz, W. (1995) · Neuropharmacology · doi:10.1016/0028-3908(95)00092-k · Cited by 311
Memantine Treatment in Mild to Moderate Alzheimer Disease: A 24-Week Randomized, Controlled Trial
Peskind, E. R., Potkin, S. G., Pomara, N., Ott, B. R., Graham, S. M., Olin, J. T., & McDonald, S. (2006) · The American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000224350.82719.83 · Cited by 307
A role for the 5-HT1A, 5-HT4 and 5-HT6 receptors in learning and memory
KING, M., MARSDEN, C., & FONE, K. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.07.001 · Cited by 304
Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease
Xu, Y., Yan, J., Zhou, P., Li, J., Gao, H., Xia, Y., & Wang, Q. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.02.002 · Cited by 301
An Introduction to Brain and Behavior
Kolb, B. E., & Whishaw, I. Q. (2019) · Cited by 292
Revett, T. J., Baker, G. B., Jhamandas, J., & Kar, S. (2013) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.110190 · Cited by 292
Chen, H. S., & Lipton, S. A. (1997) · The Journal of Physiology · doi:10.1113/jphysiol.1997.sp021909 · Cited by 282
Parsons, C. G., Gruner, R., Rozental, J., Millar, J., & Lodge, D. (1993) · Neuropharmacology · doi:10.1016/0028-3908(93)90029-3 · Cited by 279
Lack of Evidence for the Efficacy of Memantine in Mild Alzheimer Disease
Schneider, L. S. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.69 · Cited by 275
Porsteinsson, A., Grossberg, G., Mintzer, J., & Olin, J. (2008) · Current Alzheimer Research · doi:10.2174/156720508783884576 · Cited by 272
The Glutamatergic System and Alzheimer???s Disease: Therapeutic Implications
Butterfield, D. A., & Pocernich, C. B. (2003) · CNS Drugs · doi:10.2165/00023210-200317090-00004 · Cited by 267
Lopez, O. L., Becker, J. T., Wahed, A. S., Saxton, J., Sweet, R. A., Wolk, D. A., Klunk, W., & DeKosky, S. T. (2009) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.158964 · Cited by 266
Neuroprotection by memantine against neurodegeneration induced by β-amyloid(1–40)
Miguel-Hidalgo, J. J., Alvarez, X. A., Cacabelos, R., & Quack, G. (2002) · Brain Research · doi:10.1016/s0006-8993(02)03731-9 · Cited by 265
The serotonergic system in ageing and Alzheimer's disease
Rodríguez, J. J., Noristani, H. N., & Verkhratsky, A. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.06.010 · Cited by 264
Trapping Channel Block of NMDA-Activated Responses By Amantadine and Memantine
Blanpied, T. A., Boeckman, F. A., Aizenman, E., & Johnson, J. W. (1997) · Journal of Neurophysiology · doi:10.1152/jn.1997.77.1.309 · Cited by 249
Adenosine: does it have a neuroprotective role after all?
de Mendonça, A., Sebastião, A. M., & Ribeiro, J. A. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(00)00033-3 · Cited by 248
Neuron loss in key cholinergic and aminergic nuclei in Alzheimer disease: a meta-analysis
Lyness, S. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00057-x · Cited by 240
The cholinergic system and hippocampal plasticity
Drever, B. D., Riedel, G., & Platt, B. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.11.037 · Cited by 240
Chen, J.-F., Sonsalla, P. K., Pedata, F., Melani, A., Domenici, M. R., Popoli, P., Geiger, J., Lopes, L. V., & de Mendonça, A. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.09.002 · Cited by 239
CURCIO, C. A., & KEMPER, T. (1984) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-198407000-00001 · Cited by 225
Liu, Y., Yoo, M.-J., Savonenko, A., Stirling, W., Price, D. L., Borchelt, D. R., Mamounas, L., Lyons, W. E., Blue, M. E., & Lee, M. K. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4218-08.2008 · Cited by 206
Prickaerts, J., van Goethem, N. P., Chesworth, R., Shapiro, G., Boess, F. G., Methfessel, C., Reneerkens, O. A. H., Flood, D. G., Hilt, D., Gawryl, M., et al. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.10.024 · Cited by 204
Alzheimer's disease: Neurofibrillary tangles in nuclei that project to the cerebral cortex
German, D. C., White, C. L., & Sparkman, D. R. (1987) · Neuroscience · doi:10.1016/0306-4522(87)90123-0 · Cited by 203
Aracava, Y., Pereira, E. F. R., Maelicke, A., & Albuquerque, E. X. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.077172 · Cited by 200
Rammes, G., Rupprecht, R., Ferrari, U., Zieglgänsberger, W., & Parsons, C. G. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01872-9 · Cited by 200
Senut, M. C., Menetrey, D., & Lamour, Y. (1989) · Neuroscience · doi:10.1016/0306-4522(89)90260-1 · Cited by 194
GABAAreceptors in aging and Alzheimer’s disease
Rissman, R. A., De Blas, A. L., & Armstrong, D. M. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04832.x · Cited by 192
A2A adenosine receptor deletion is protective in a mouse model of Tauopathy
Laurent, C., Burnouf, S., Ferry, B., Batalha, V. L., Coelho, J. E., Baqi, Y., Malik, E., Mariciniak, E., Parrot, S., Van der Jeugd, A., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2014.151 · Cited by 188
Roth, M., Mountjoy, C. Q., Amrein, R., & The International Collaborative Study Group (1996) · British Journal of Psychiatry · doi:10.1192/bjp.168.2.149 · Cited by 188
Pharmacodynamics of Memantine: An Update
Parsons, C., Rammes, G., & Danysz, W. (2008) · Current Neuropharmacology · doi:10.2174/157015908783769671 · Cited by 183
Understanding Aspects of Aluminum Exposure in Alzheimer's Disease Development
Kandimalla, R., Vallamkondu, J., Corgiat, E. B., & Gill, K. D. (2016) · Brain Pathology · doi:10.1111/bpa.12333 · Cited by 183
Self-citationReynolds, G. P., Mason, S. L., Meldrum, A., De Keczer, S., Parties, H., Eglen, R. M., & Wong, E. H. F. (1995) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1995.tb13303.x · Cited by 180
Open-Channel Blockers at the Human α4β2 Neuronal Nicotinic Acetylcholine Receptor
Buisson, B., & Bertrand, D. (1998) · Molecular Pharmacology · doi:10.1124/mol.53.3.555 · Cited by 179
Marcade, M., Bourdin, J., Loiseau, N., Peillon, H., Rayer, A., Drouin, D., Schweighoffer, F., & Désiré, L. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05396.x · Cited by 175
Adenosine receptor antagonists for cognitive dysfunction: a review of animal studies
Takahashi, R. N. (2008) · Frontiers in Bioscience · doi:10.2741/2870 · Cited by 174
Fisher, A. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.002 · Cited by 174
Corradi, J., & Bouzat, C. (2016) · Molecular Pharmacology · doi:10.1124/mol.116.104240 · Cited by 167
Neuronal histamine deficit in Alzheimer's disease
Panula, P., Rinne, J., Kuokkanen, K., Eriksson, K. S., Sallmen, T., Kalimo, H., & Relja, M. (1997) · Neuroscience · doi:10.1016/s0306-4522(97)00353-9 · Cited by 165
Histamine H3 receptor as a potential target for cognitive symptoms in neuropsychiatric diseases
Sadek, B. S., Saad, A. K., Sadeq, A. S., Jalal, F. Y., & Stark, H. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.06.051 · Cited by 162
Espinosa, J., da Rocha, A. S., Nunes, F., da Costa, M. S., Schein, V., Kazlauckas, V., Kalinine, E., Souza, D. O., Cunha, R. A., & Porciúncula, L. O. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-111982 · Cited by 160
Oxidative Imbalance in Alzheimer's Disease
Zhu, X., Lee, H., Casadesús, G., Ávila, J., Drew, K. L., Perry, G. L., & Smith, M. A. (2005) · Molecular Neurobiology · doi:10.1385/mn:31:1-3:205 · Cited by 160
Lahmy, V., Meunier, J., Malmström, S., Naert, G., Givalois, L., Kim, S. H., Villard, V., Vamvakides, A., & Maurice, T. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.70 · Cited by 159
Wang, J., Yu, J., Wang, H.-F., Meng, X., Wang, C., Tan, C., & Tan, L. (2014) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-308112 · Cited by 159
Multiple faces of dynamin-related protein 1 and its role in Alzheimer's disease pathogenesis
Kandimalla, R. J. L., & Reddy, P. H. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.12.018 · Cited by 156
Self-citationAlzheimer Disease and the Role of Free Radicals in the Pathogenesis of the Disease
Perry, G. L., Moreira, P. I., Santos, M. S., Oliveira, C. R., Shenk, J. C., Nunomura, A., Smith, M. A., & Zhu, X. (2008) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152708783885156 · Cited by 155
Fisher, A. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07507.x · Cited by 154
Finkel, S. I., Mintzer, J. E., Dysken, M. W., Krishnan, K., Burt, T., & McRae, T. D. (2004) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.998 · Cited by 153
Increased Autophagic Degradation of Mitochondria in Alzheimer Disease
Moreira, P. I., Siedlak, S. L., Wang, X., Santos, M. S., Oliveira, C. R., Tabaton, M., Nunomura, A., Szweda, L. I., Aliev, G., Smith, M. A., et al. (2007) · Autophagy · doi:10.4161/auto.4872 · Cited by 152
Vilaró, M. T., Cortés, R., & Mengod, G. (2005) · The Journal of Comparative Neurology · doi:10.1002/cne.20447 · Cited by 148
Alzheimer's disease: diverse aspects of mitochondrial malfunctioning.
Santos, R. X., Correia, S. C., Wang, X., Perry, G. L., Smith, M. A., Moreira, P. I., & Zhu, X. (2010) · Europe PMC (PubMed Central) · Cited by 147
Oxidative Stress: The Old Enemy in Alzheimers Disease Pathophysiology
Moreira, P. I., Honda, K., Liu, Q., Santos, M. S., Oliveira, C. R., Aliev, G., Nunomura, A., Zhu, X., Smith, M. A., & Perry, G. L. (2005) · Current Alzheimer Research · doi:10.2174/156720505774330537 · Cited by 147
Histamine H1 receptors in patients with Alzheimer’s disease assessed by positron emission tomography
Higuchi, M., Yanai, K., Okamura, N., Meguro, K., Arai, H., Itoh, M., Iwata, R., Ido, T., Watanabe, T., & Sasaki, H. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00230-x · Cited by 145
Bakchine, S., & Loft, H. (2007) · Journal of Alzheimer s Disease · doi:10.3233/jad-2007-11409 · Cited by 140
Winblad, B., Grossberg, G., Frölich, L., Farlow, M., Zechner, S., Nagel, J., & Lane, R. (2007) · Neurology · doi:10.1212/01.wnl.0000281847.17519.e0 · Cited by 136
Schechter, L. E., Smith, D. L., Rosenzweig-Lipson, S. J., Rizzo, S. J. S., Dawson, L. A., Marquis, K. L., Jones, D., Piesla, M. J., Andree, T. H., Nawoschik, S. P., et al. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.086363 · Cited by 135
Banerjee, P., Samoriski, G., & Gupta, S. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.081976 · Cited by 134
EHT0202 in Alzheimers Disease: A 3-Month, Randomized, Placebo- Controlled, Double-Blind Study
Vellas, B., Sol, O., J. Snyder, P., Ousset, P.-J., Haddad, R., Maurin, M., Lemarie, J.-C., Desire, L., & P. Pando, M. (2011) · Current Alzheimer Research · doi:10.2174/156720511795256053 · Cited by 133
Silva, D. F., Selfridge, J. E., Lu, J., E, L., Roy, N., Hutfles, L., Burns, J. M., Michaelis, E. K., Yan, S., Cardoso, S. M., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt247 · Cited by 133
Sberna, G., Sáez‐Valero, J., Beyreuther, K. T., Masters, C. L., & Small, D. H. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69031177.x · Cited by 132
Lefèvre, G. Y., Sedek, G., Jhee, S. S., Leibowitz, M. T., Huang, H.-L., Enz, A., Maton, S., Ereshefsky, L., Pommier, F., Schmidli, H., et al. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100242 · Cited by 130
Neuronal failure in Alzheimer’s disease: a view through the oxidative stress looking-glass
Bonda, D., Wang, X., Lee, H., Smith, M. A., Perry, G. L., & Zhu, X. (2014) · Neuroscience Bulletin · doi:10.1007/s12264-013-1424-x · Cited by 128
DNA methylation based biomarkers in colorectal cancer: A systematic review
Lam, K., Pan, K., Linnekamp, J. F., Medema, J. P., & Kandimalla, R. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.07.001 · Cited by 128
Self-citationLoss of Muscarinic M1 Receptor Exacerbates Alzheimer's Disease–Like Pathology and Cognitive Decline
Medeiros, R., Kitazawa, M., Caccamo, A., Baglietto‐Vargas, D., Estrada-Hernandez, T., Cribbs, D. H., Fisher, A., & LaFerla, F. M. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.04.041 · Cited by 127
Atri, A., Molinuevo, J. L., Lemming, O., Wirth, Y., Pulte, I., & Wilkinson, D. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt160 · Cited by 126
Atack, J. R. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.09.001 · Cited by 123
Amyloid- Impairs Synaptic Inhibition via GABAA Receptor Endocytosis
Ulrich, D. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.0950-15.2015 · Cited by 122
Cholinergic influences on cortical development and adult neurogenesis
Bruel‐Jungerman, E., Lucassen, P. J., & Francis, F. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.01.021 · Cited by 122
Hendricksen, M., Thomas, A. J., Ferrier, I. N., Ince, P., & O’Brien, J. T. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.6.1096 · Cited by 121
[3H]-GR113808 labels 5-HT4 receptors in the human and guinea-pig brain
Waeber, C., Sebben, M., Grossman, C. P., Javoy-Agid, F., Bockaert, J., & Dumuis, A. (1993) · Neuroreport · doi:10.1097/00001756-199309000-00007 · Cited by 118
Chen, C., Eastwood, S. L., Hope, T., McDonald, B., Francis, P. T., & Esiri, M. M. (2000) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.2000.00254.x · Cited by 118
Dinamarca, M. C., Ríos, J. A., & Inestrosa, N. C. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00464 · Cited by 117
Maher‐Edwards, G., Zvartau-Hind, M. E., Hunter, A. J., Gold, M., Hopton, G., Jacobs, G., Davy, M., & Williams, P. M. (2010) · Current Alzheimer Research · doi:10.2174/156720510791383831 · Cited by 117
Parsons, C. G., Panchenko, V. A., Pinchenko, V. O., Tsyndrenko, A. Y., & Krishtal, O. A. (1996) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1996.tb01228.x · Cited by 114
Toyohara, J., & Hashimoto, K. (2010) · The Open Medicinal Chemistry Journal · doi:10.2174/1874104501004010037 · Cited by 114
SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study
Maher‐Edwards, G., Dixon, R., Hunter, J. A., Gold, M., Hopton, G., Jacobs, G., Hunter, J., & Williams, P. M. (2010) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2562 · Cited by 113
Experimental studies on the role of serotonin in cognition
Sirviö, J., Riekkinen, P. J., Jäkälä, P., & Riekkinen, P. J. (1994) · Progress in Neurobiology · doi:10.1016/0301-0082(94)90060-4 · Cited by 113
Zajaczkowski, W., Frankiewicz, T., Parsons, C. G., & Danysz, W. (1997) · Neuropharmacology · doi:10.1016/s0028-3908(97)00070-1 · Cited by 112
Cell loss in the nucleus raphes dorsalis in alzheimer's disease
Aletrino, M. A., Vogels, O. J. M., van Domburg, P. H. M. F., & ten Donkelaar, H. J. (1992) · Neurobiology of Aging · doi:10.1016/0197-4580(92)90073-7 · Cited by 111
Molecular Rearrangements of the Extracellular Vestibule in NMDAR Channels during Gating
Sobolevsky, A. I., Beck, C., & Wollmuth, L. P. (2002) · Neuron · doi:10.1016/s0896-6273(01)00560-8 · Cited by 111
Bakchine, S., & Loft, H. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-13110 · Cited by 111
Frankiewicz, T., & Parsons, C. G. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00060-x · Cited by 110
Brain stem serotonin-synthesizing neurons in Alzheimer's disease: a clinicopathological correlation
Halliday, G. M., McCann, H., Pamphlett, R., Brooks, W. S., Creasey, H. M., McCusker, E. A., Cotton, R. G. H., Broe, G. A., & Harper, C. (1992) · Acta Neuropathologica · doi:10.1007/bf00227741 · Cited by 109
Grove, R. A., Harrington, C. M., Mahler, A., Beresford, I. J. M., Maruff, P. T., Lowy, M. T., Nicholls, A. J., Boardley, R., Berges, A., Nathan, P. J., et al. (2014) · Current Alzheimer Research · doi:10.2174/1567205010666131212110148 · Cited by 109
DANTOINE, T. F., Auriacombe, S., Sarazin, M., Becker, H., Pere, J.-J., & Bourdeix, I. (2005) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2005.00769.x · Cited by 108
Neuronal histamine and cognitive symptoms in Alzheimer's disease
Zlomuzica, A., Dere, D., Binder, S., Silva, M. A. D. S., Huston, J. P., & Dere, E. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.05.007 · Cited by 105
The human histaminergic system in neuropsychiatric disorders
Shan, L., Bao, A., & Swaab, D. F. (2015) · Trends in Neurosciences · doi:10.1016/j.tins.2014.12.008 · Cited by 105
Berger-Sweeney, J. E. (2003) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(03)00070-8 · Cited by 102
Effects of memantine on recombinant rat NMDA receptors expressed in HEK 293 cells
Bresink, I., Benke, T. A., Collett, V. J., Seal, A., Parsons, C. G., Henley, J. M., & Collingridge, G. L. (1996) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1996.tb15971.x · Cited by 102
Calcium flux-independent NMDA receptor activity is required for Aβ oligomer-induced synaptic loss
Birnbaum, J. H., Bali, J., Rajendran, L., Nitsch, R. M., & Tackenberg, C. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.160 · Cited by 101
Sharma, D. R., Wani, W. Y., Sunkaria, A., Kandimalla, R. J. L., Verma, D., Cameotra, S. S., & Gill, K. D. (2012) · Neurotoxicity Research · doi:10.1007/s12640-012-9351-6 · Cited by 99
Self-citationSlotkin, T. A., Seidler, F. J., Crain, B. J., Bell, J. M., Bissette, G., & Nemeroff, C. B. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.7.2452 · Cited by 99
Adenosine A 2 A receptors are necessary and sufficient to trigger memory impairment in adult mice
Pagnussat, N., Almeida, A. S., Marques, D. M., Nunes, F., Chenet, G. C., Botton, P. H. S., Mioranzza, S., Loss, C. M., Cunha, R. A., & Porciúncula, L. O. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13180 · Cited by 97
Mazurkiewicz-Kwilecki, I. M., & Nsonwah, S. (1989) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y89-013 · Cited by 96
5-HT7 receptors in the modulation of cognitive processes
Cifariello, A., Pompili, A., & Gasbarri, A. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.12.012 · Cited by 94
Histamine function in brain disorders
Fernández‐Novoa, L., & Cacabelos, R. (2001) · Behavioural Brain Research · doi:10.1016/s0166-4328(01)00215-7 · Cited by 94
Modulation of behavior by the histaminergic system: Lessons from HDC-, H3R- and H4R-deficient mice
Schneider, E. H., Neumann, D., & Seifert, R. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.07.020 · Cited by 91
Functional roles of neurotransmitters and neuromodulators in the dorsal striatum
Do, J., Kim, J., Bakes, J., Lee, K., & Kaang, B. (2012) · Learning & Memory · doi:10.1101/lm.025015.111 · Cited by 90
AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for alzheimer’s disease
Fisher, A., Brandeis, R., Bar-Ner, R. H. N., Kliger-Spatz, M., Natan, N., Sonego, H., Marcovitch, I., & Pittel, Z. (2002) · Journal of Molecular Neuroscience · doi:10.1007/s12031-002-0025-3 · Cited by 89
Cotinine: A Potential New Therapeutic Agent against Alzheimer's disease
Echeverría, V., & Zeitlin, R. (2012) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2012.00317.x · Cited by 86
Ni, R., Marutle, A., & Nordberg, A. K. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121447 · Cited by 85
Alterations in the histaminergic system in Alzheimer's disease: a postmortem study
Shan, L., Bossers, K., Unmehopa, U., Bao, A.-M., & Swaab, D. F. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.12.026 · Cited by 84
Maskell, P., Spéder, P., Newberry, N. R., & Bermúdez, I. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705559 · Cited by 84
Brain histamine in Alzheimer's disease.
Cacabelos, R., Yamatodani, A., Niigawa, H., Hariguchi, S., Tada, K., Nishimura, T., Wada, H., Brandeis, L., & Pearson, J. (1989) · PubMed · Cited by 83
Molecular Mechanisms Underlying Memory Consolidation of Taste Information in the Cortex
Gal-Ben-Ari, S., & Rosenblum, K. (2012) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2011.00087 · Cited by 82
Gilling, K. E., Jatzke, C., Hechenberger, M., & Parsons, C. G. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.01.012 · Cited by 82
Nucleus-specific alteration of raphe neurons in human neurodegenerative disorders
Kovács, G. G., Klöppel, S., Fischer, I., Dorner, S., Lindeck‐Pozza, E., Birner, P., Bötefür, I. C., Pilz, P. K. D., Volk, B., & Budka, H. (2003) · Neuroreport · doi:10.1097/00001756-200301200-00014 · Cited by 81
Shen, F., Smith, J. A. M., Chang, R., Bourdet, D. L., Tsuruda, P. R., Obedencio, G. P., & Beattie, D. T. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.02.026 · Cited by 79
A Randomized Study of H3 Antagonist ABT-288 in Mild-To-Moderate Alzheimer's Dementia1
Haig, G. M., Pritchett, Y., Meier, A., Othman, A. A., Hall, C. M., Gault, L. M., & Lenz, R. A. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140291 · Cited by 78
Cholinesterase inhibitors for rarer dementias associated with neurological conditions
Li, Y., Hai, S., Zhou, Y., & Dong, B. R. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009444.pub3 · Cited by 78
Non-cholinergic Effects of Huperzine A: Beyond Inhibition of Acetylcholinesterase
Zhang, H., Yan, H., & Tang, X. C. (2007) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-007-9163-z · Cited by 78
?7 Nicotinic Acetylcholine Receptors in Alzheimer's Disease: Neuroprotective, Neurotrophic or Both?
Hernandez, C. M., & Dineley, K. T. (2012) · Current Drug Targets · doi:10.2174/138945012800398973 · Cited by 76
The Neglected Role of Histamine in Alzheimer’s Disease
Naddafi, F., & Mirshafiey, A. (2013) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317513488925 · Cited by 74
Domènech, T., Beleta, J., Fernández, A. G., Gristwood, R. W., Sánchez, F. C., Tolosa, E., & Palacios, J. M. (1994) · Molecular Brain Research · doi:10.1016/0169-328x(94)90392-1 · Cited by 73
Molino, I., Colucci, L., Fasanaro, A. M., Traini, E., & Amenta, F. (2013) · The Scientific World JOURNAL · doi:10.1155/2013/925702 · Cited by 73
Memogain is a Galantamine Pro-drug having Dramatically Reduced Adverse Effects and Enhanced Efficacy
Maelicke, A., Hoeffle-Maas, A., Ludwig, J., Maus, A. D. J., Samochocki, M., Jordis, U., & Koepke, A. K. E. (2009) · Journal of Molecular Neuroscience · doi:10.1007/s12031-009-9269-5 · Cited by 73
Sigma receptor modulators: a patent review
Collina, S., Gaggeri, R., Marra, A., Bassi, A., Negrinotti, S., Negri, F., & Rossi, D. (2013) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2013.769522 · Cited by 71
The organization and neural substrates of human memory.
Lr, S. (1987) · PubMed · Cited by 70
Nathan, P. J., Boardley, R., Scott, N. E., Berges, A., Maruff, P. T., Sivananthan, T., Upton, N., Lowy, M. T., Nestor, P. J., & Lai, R. Y. K. (2013) · Current Alzheimer Research · doi:10.2174/1567205011310030003 · Cited by 69
Siddique, H., Hynan, L. S., & Weiner, M. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04828 · Cited by 68
Parri, H. R., & Dineley, K. T. (2010) · Current Alzheimer Research · doi:10.2174/156720510790274464 · Cited by 67
The histamine H1‐receptor mediates the motivational effects of novelty
Zlomuzica, A., Viggiano, D., Silva, M. A. D. S., Ishizuka, T., Carnevale, U. A. G., RUOCCO, L. A., Watanabe, T., Sadile, A. G., Huston, J. P., & Dere, E. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06115.x · Cited by 66
Bitner, R. S., Markosyan, S., Nikkel, A. L., & Brioni, J. D. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.10.026 · Cited by 66
Reid, P. R., Bridges, T. M., Sheffler, D. J., Cho, H. P., Lewis, L. M., Days, E., Daniels, J. S., Jones, C. K., Niswender, C. M., Weaver, C. D., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.12.015 · Cited by 66
Mizukami, K., Ikonomović, M. D., Grayson, D. R., Sheffield, R., & Armstrong, D. M. (1998) · Brain Research · doi:10.1016/s0006-8993(98)00437-5 · Cited by 65
Köles, L., Kató, E., Hanuska, A., Zádori, Z., Al‐Khrasani, M., Zelles, T., Rubini, P., & Illés, P. (2015) · Purinergic Signalling · doi:10.1007/s11302-015-9480-5 · Cited by 65
Serotonin 6 receptor controls alzheimer’s disease and depression
Yun, H.-M., Park, K.-R., Kim, E.-C., Kim, S., & Hong, J. T. (2015) · Oncotarget · doi:10.18632/oncotarget.5777 · Cited by 62
Two Blocking Sites of Amino-Adamantane Derivatives in Open N-Methyl-d-Aspartate Channels
Sobolevsky, A. I., & Koshelev, S. G. (1998) · Biophysical Journal · doi:10.1016/s0006-3495(98)77844-0 · Cited by 60
The role of metabotropic glutamate receptors in Alzheimer's disease
Lee, H., Zhu, X., O'Neill, M., Webber, K. M., Casadesús, G., Marlatt, M. W., Raina, A. K., Perry, G. L., & Smith, M. A. (2004) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2004-1494 · Cited by 59
Hellweg, R., Wirth, Y., Janetzky, W., & Hartmann, S. (2011) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2766 · Cited by 57
Medhurst, A. D., Roberts, J., Lee, J., Chen, C., Brown, S., Roman, S. A., & Lai, M. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00075.x · Cited by 57
Modulation of behavior by the histaminergic system: Lessons from H1R-and H2R-deficient mice
Schneider, E. H., Neumann, D., & Seifert, R. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.03.009 · Cited by 57
Lagostena, L., Rosato‐Siri, M. D., D’Onofrio, M., Brandi, R., Arisi, I., Capsoni, S., Franzot, J., Cattaneo, A., & Cherubini, E. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.3326-09.2010 · Cited by 56
Rozzini, L., Chilovi, B. V., Conti, M. Z., Bertoletti, E., Zanetti, M., Trabucchi, M., & Padovani, A. (2009) · International Psychogeriatrics · doi:10.1017/s1041610209990184 · Cited by 56
Jia, J., Zhao, Q., Liu, Y., Gui, Y., Liu, G., Zhu, D., Yu, C., & Hong, Z. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2013.7 · Cited by 55
Histamine H1 receptor knockout mice exhibit impaired spatial memory in the eight‐arm radial maze
Zlomuzica, A., RUOCCO, L. A., Sadile, A. G., Huston, J. P., & Dere, E. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00225.x · Cited by 54
Dere, E., Zlomuzica, A., Viggiano, D., Ruocco, L. A., Watanabe, T., Sadile, A. G., Huston, J. P., & Souza‐Silva, M. A. D. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.09.025 · Cited by 51
The histamine H3-receptor inverse agonist Pitolisant improves fear memory in mice
Brabant, C., Charlier, Y., & Tirelli, E. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.12.063 · Cited by 51
Zolles, G., Wagner, E., Lampert, A., & Sutor, B. (2008) · Cerebral Cortex · doi:10.1093/cercor/bhn158 · Cited by 49
β‐amyloid cortical deposits are accompanied by the loss of serotonergic neurons in the dog
Bernedo, V., Insua, D., Suarez, M. L., Santamarina, G., Sarasa, M., & Pesini, P. (2009) · The Journal of Comparative Neurology · doi:10.1002/cne.21985 · Cited by 48
Therapeutic options in Alzheimer’s disease
Moreira, P. I., Zhu, X., Nunomura, A., Smith, M. A., & Perry, G. L. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.6.897 · Cited by 47
Mizukami, K., Ikonomović, M. D., Grayson, D. R., Rubín, R. T., Warde, D., Sheffield, R., Hamilton, R. L., Davies, P., & Armstrong, D. M. (1997) · Experimental Neurology · doi:10.1006/exnr.1997.6591 · Cited by 46
Erratum: A2A adenosine receptor deletion is protective in a mouse model of Tauopathy
Laurent, C., Burnouf, S., Ferry, B., Batalha, V. L., Coelho, J. E., Baqi, Y., Malik, E. M., Mariciniak, E., Parrot, S., der Jeugd, A. V., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.115 · Cited by 44
Ebinger, G., Bruyland, M., Martin, J. J., Herregodts, P., Cras, P. P., Michotte, Y. M., & Gommé, L. (1987) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(87)90128-6 · Cited by 43
Apo-E4 Allele in Conjunction with Aβ42 and Tau in CSF: Biomarker for Alzheimers Disease
Kandimalla, R. J. L., Prabhakar, S., Binukumar, B. K., Wani, W. Y., Gupta, N., Sharma, D. R., Sunkaria, A., Grover, V., Bhardwaj, N., Jain, K., et al. (1970) · Current Alzheimer Research · doi:10.2174/156720511795256071 · Cited by 43
Self-citationCafeína, receptores de adenosina, memoria y enfermedad de Alzheimer
Cunha, R. A. (2008) · Medicina Clínica · doi:10.1016/s0025-7753(08)75506-4 · Cited by 41
Provensi, G., Costa, A., Passani, M. B., & Blandina, P. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.06.010 · Cited by 41
Anisuzzaman, A. S. M., Uwada, J., Masuoka, T., Yoshiki, H., Nishio, M., Ikegaya, Y., Takahashi, N., Matsuki, N., Fujibayashi, Y., Yonekura, Y., et al. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12306 · Cited by 39
Marazziti, D., Baroni, S., Pirone, A., Giannaccini, G., Betti, L., Schmid, L., Vatteroni, E., Palego, L., Borsini, F., Bordi, F., et al. (2012) · Neurochemical Research · doi:10.1007/s11064-011-0684-y · Cited by 39
Klugman, A., Naughton, D. P., Isaac, M. G. E. K. N., Shah, I., Petróczi, A., & Tabet, N. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120124 · Cited by 36
Riepe, M. W., Adler, G., Ibach, B., Weinkauf, B., Tracik, F. M., & Günay, İ. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000100875 · Cited by 35
Substrate-binding sites in acetylcholinesterase
Hucko, F., Järv, J., & Weise, C. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90621-x · Cited by 32
CSF Ubiquitin As a Specific Biomarker in Alzheimer's Disease
Kandimalla, R. J. L., Anand, R., Veeramanikandan, R., Wani, W. Y., Prabhakar, S. K., Grover, V. K., Bharadwaj, N., Jain, K., & Gill, K. (2014) · Current Alzheimer Research · doi:10.2174/1567205011666140331161027 · Cited by 32
Self-citationsiRNA against presenilin 1 (PS1) down regulates amyloid β42 production in IMR-32 cells
Kandimalla, R. J. L., Wani, W. Y., Binukumar, B. K., & Gill, K. D. (2012) · Journal of Biomedical Science · doi:10.1186/1423-0127-19-2 · Cited by 31
Self-citationAmbrée, O., Buschert, J., Zhang, W., Arolt, V., Dere, E., & Zlomuzica, A. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.04.006 · Cited by 29
α7-nAChR agonist enhances neural plasticity in the hippocampus via a GABAergic circuit
Townsend, M., Whyment, A. D., Walczak, J., Jeggo, R., van den Top, M., Flood, D. G., Leventhal, L., Patzke, H., & Koenig, G. (2016) · Journal of Neurophysiology · doi:10.1152/jn.00243.2016 · Cited by 29
Kandimalla, R. J. L., Prabhakar, S., Binukumar, B. K., Wani, W. Y., Sharma, D. R., Grover, V., Bhardwaj, N., Jain, K., & Gill, K. D. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.06.075 · Cited by 28
Self-citationMotawaj, M., Burban, A., Davenas, E., & Arrang, J. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.174458 · Cited by 28
Nakaya, K., Nakagawasai, O., Arai, Y., Onogi, H., Sato, A., Niijima, F., Tan–No, K., & Tadano, T. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.11.053 · Cited by 26
Patat, A. A., Parks, V., Raje, S. V., et al. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2008.03348.x · Cited by 26
Lee, R. H., Tseng, T.-Y., Wu, C. Y., Chen, P., Chen, M., Kuo, J., & Lee, T. J.-F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040326 · Cited by 23
Chen, P., Tsai, C.-T., OU, C.-Y., et al. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2012.757 · Cited by 22
Smad3 deficiency inhibits dentate gyrus LTP by enhancing GABAA neurotransmission
Muñoz, M.-D., Antolín‐Vallespín, M., Tapia‐González, S., & Sánchez‐Capelo, A. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13558 · Cited by 22
Wani, W. Y., Kandimalla, R. J. L., Sharma, D. R., Kaushal, A., Anand, R., Sunkaria, A., Vallamkondu, J., Chiarugi, A., Reddy, P. H., & Gill, K. D. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.05.014 · Cited by 22
Self-citation
Cited by
Gut microbiota and dysbiosis in Alzheimer's disease: Implications for pathogenesis and treatment
Liu, S., Gao, J., Zhu, M., Liu, K., & Zhang, H.-L. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02073-3 · Cited by 516
The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease
the Synaptic Health Endpoints Working Group, Colom-Cadena, M., Spires-Jones, T., Zetterberg, H., Blennow, K., Caggiano, A., DeKosky, S. T., Fillit, H., Harrison, J. E., Schneider, L. S., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00588-4 · Cited by 328
Revisiting the role of neurotransmitters in epilepsy: An updated review
Akyuz, E., Polat, A. K., Eroglu, E., Kullu, I., Angelopoulou, E., & Paudel, Y. N. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.118826 · Cited by 303
A Perspective on Multi-target Drugs for Alzheimer’s Disease
Benek, O., Korabecny, J., & Soukup, O. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.04.008 · Cited by 260
Jeon, M.-T., Kim, K.-S., Kim, E. S., Lee, S., Kim, J., Hoe, H.-S., & Kim, D.-G. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101333 · Cited by 76
Metadata
- Authors
- Kandimalla, R., & Reddy, P. H.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2017-02-15
- Volume
- 57
- Issue
- 4
- Pages
- 1049-1069
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2588517921
- Cited by
- 268
- References
- 210
- FWCI
- 8.41
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.